Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance

(RTTNews) - Telix Pharmaceuticals Ltd. (TLX), a commercial-stage company, reported a 19% increase in group revenue and highlighted key operational achievements for the third quarter ended September 30, 2026. The company also reaffirmed its full-year 2026 revenue guidance.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Finance & Markets

BYD to rely on imports initially, Hubco says

KARACHI: Hub Power Company (Hubco) has said that BYD vehicle production will initially rely entirely on imported raw materials and components, with localisation increasing gradually over time. The long-term objective is to localise up to 80 per cent of the vehicle, which should improve cost competitiveness and reduce reliance on imports…

Hong Kong stocks open higher

Local and regional stocks rose on Wednesday following Wall Street's gains as early indications from the corporate earnings season pointed to strong profits for global companies and bolstered investor confidence. Hong Kong's Hang Seng Index rose 271 points, or 1.14 percent, to open at 24,139.

More from Wednesday 21 October →